Evidence map›Paper›PMID 41396117›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025

The association between sarcoidosis and lymphoma: a retrospective and multicentre study of 46 patients.

Romé Charriere, Thomas El Jammal, Arthur Bert, Emilie Chalayer, Martin Kilian, Mathieu Gerfaud-Valentin, Yvan Jamilloux, Hervé Ghesquieres, Pascal Seve

Abstract read
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Romé CharriereDepartment of Internal Medicine, Hôpital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France.
Thomas El JammalDepartment of Internal Medicine, Hôpital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France.
Arthur BertDepartment of Internal Medicine, Hôpital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France.
Emilie ChalayerUniversity Cancerology and Hematology Institute, Centre Hospitalier Universitaire, Saint-Etienne, France.
Martin KilianUniversity Cancerology and Hematology Institute, Centre Hospitalier Universitaire, Saint-Etienne, France.
Mathieu Gerfaud-ValentinDepartment of Internal Medicine, Hôpital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France.
Yvan JamillouxDepartment of Internal Medicine, Hôpital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France.
Hervé GhesquieresDepartment of Hematology, Hôpital de Lyon Sud, Université Claude Bernard Lyon I, Lyon, France.
Pascal SeveDepartment of Internal Medicine, Hôpital de la Croix-Rousse, Université Claude Bernard Lyon I, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies on sarcoidosis-lymphoma syndrome are scarce, and the association between these diseases is poorly understood.   Aim: To analyse the features of three types of sarcoidosis-lymphoma association (SLA) according to the time of diagnosis of both diseases and to compare the features of patients who presented with sarcoidosis before lymphoma with those of patients with sarcoidosis alone (SA) in order to identify predictive factors of lymphoma development.   Design: A multicentre retrospective comparative study was conducted in two hospitals in Lyon and one hospital in Saint-Etienne, France, between 1999 and 2022.   Methods: In the SLA group, 46 patients were included and compared to 92 patients of the SA group. Demographic characteristics, medical history, clinical presentation, laboratory and imaging findings, treatments, and outcomes were collected and analysed from medical records.   Results: The age at lymphoma diagnosis was significantly higher in the group in which sarcoidosis preceded lymphoma [65.9 years when sarcoidosis preceded lymphoma vs 48.3 years when both diseases occurred simultaneously vs 44.5 years when sarcoidosis followed lymphoma, p<0.001]. Hodgkin's lymphoma was significantly more frequent in patients from group "simultaneous diseases" (p<0.001). There were significantly more autoimmune diseases (15.2% vs 2.17% p=0.007) in the SLA group, and patients with SA presented more frequently with night sweats (45.7% vs 11.6% p<0.001).   Conclusions: No robust predictive factor of lymphoma development in patients with sarcoidosis was identified. However, it highlighted distinct clinical scenarios according to when lymphoma is diagnosed that must be taken into account by clinicians for disease management.

Identifiers

PMID41396117
PMCPMC12815286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.